Survival improvement for patients with metastatic colorectal cancer over twenty years

Failure to Cure Patients with Colorectal Liver Metastases: The Impact of the Liver Surgeon

(2021) Eduardo A. Vega et al.   ANNALS OF SURGICAL ONCOLOGY

Advances in radiological staging of colorectal cancer

(2021) R.J. Goiffon et al.   CLINICAL RADIOLOGY

Improved Survival over Time After Resection of Colorectal Liver Metastases and Clinical Impact of Multigene Alteration Testing in Patients with Metastatic Colorectal Cancer

(2021) Yoshikuni Kawaguchi et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer

(2021) Yoshikuni Kawaguchi et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Neither Surgical Margin Status nor Somatic Mutation Predicts Local Recurrence After R0-intent Resection for Colorectal Liver Metastases

(2021) Yujiro Nishioka et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

(2020) Chiara Cremolini et al.   LANCET ONCOLOGY

Systematic failure to operate on colorectal cancer liver metastases in California

(2020) Mustafa Raoof et al.   Cancer Medicine

BRAF Mutated Colorectal Cancer: New Treatment Approaches

(2020) Javier Molina-Cerrillo et al.   Cancers

Choices of Therapeutic Strategies for Colorectal Liver Metastases Among Expert Liver Surgeons

(2020) Povilas Ignatavicius et al.   ANNALS OF SURGERY

RAS/TP53 co-Mutation is Associated with Worse Survival after Concurrent Resection of Colorectal Liver Metastases and Extrahepatic Disease

(2020) Heather A. Lillemoe et al.   ANNALS OF SURGERY

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

(2020) Thierry André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation

(2019) Yoshikuni Kawaguchi et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Mutation Status of RAS, TP53, and SMAD4 is Superior to Mutation Status of RAS Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases

(2019) Yoshikuni Kawaguchi et al.   CLINICAL CANCER RESEARCH

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

(2019) Scott Kopetz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

(2019) Dung T. Le et al.   JOURNAL OF CLINICAL ONCOLOGY

Colorectal Cancer Disparity in African Americans

(2018) Gaius J. Augustus et al.   AMERICAN JOURNAL OF PATHOLOGY

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

(2018) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer

(2017) Alan P. Venook et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors

(2017) Rajyalakshmi Luthra et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

(2017) Michael J Overman et al.   LANCET ONCOLOGY

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases

(2017) Yun Shin Chun et al.   ANNALS OF SURGERY

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

(2016) E. Van Cutsem et al.   ANNALS OF ONCOLOGY

Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus

(2015) René Adam et al.   CANCER TREATMENT REVIEWS

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer

(2015) Ryan B. Corcoran et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma

(2014) Christina Hackl et al.   BMC CANCER

Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution

(2014) S. Misale et al.   Cancer Discovery

Landmark analysis to adjust for immortal time bias in oncology studies using claims data linked to death data

(2013) A.M. Farr et al.   VALUE IN HEALTH

Selection for hepatic resection of colorectal liver metastases: expert consensus statement

(2013) Reid B. Adams et al.   HPB

Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series

(2010) A. E. M. van der Pool et al.   Colorectal Disease

Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel

(2009) B. Nordlinger et al.   ANNALS OF ONCOLOGY

Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy

(2009) Scott Kopetz et al.   JOURNAL OF CLINICAL ONCOLOGY